A brief personal history of cancer immunotherapy at Stanford: if these walls could talk…
Tóm tắt
This is a journey that began in medical school at Stanford in 1963 and that is still underway, now as faculty member here for the past 40 years. History is by its nature selective, and I chose highlights that reflect on the remarkable progress we have made using the immune system to treat cancer. We will never be satisfied until we eliminate suffering and early mortality from cancer, but the progress is indeed remarkable as are the people who have contributed to it.
Tài liệu tham khảo
Hurwitz E, Levy R, Maron R, Wilchek M, Arnon R, Sela M. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res. 1975;35(5):1175–81.
Levy R, Hurwitz E, Maron R, Arnon R, Sela M. The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies. Cancer Res. 1975;35(5):1182–6 Epub 1975/05/01.
Levy R, Warnke R, Dorfman RF, Haimovich J. The monoclonality of human B-cell lymphomas. J Exp Med. 1977;145(4):1014–28 Epub 1977/04/01.
Levy R, Dilley J. The in vitro antibody response to cell surface antigens. II. Monoclonal antibodies to human leukemia cells. J Immunol. 1977;119(2):394–400 Epub 1977/08/01.
Levy R, Dilley J. The in vitro antibody response to cell surface antigens. I. The xenogeneic response to human leukemia cells. J Immunol. 1977;119(2):387–93 Epub 1977/08/01.
Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.
Levy R, Dilley J. Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. Proc Natl Acad Sci USA. 1978;75(5):2411–5 Epub 1978/05/01.
Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306(9):517–22 Epub 1982/03/04.
Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84(8):2457–66 Epub 1994/10/15.
Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117(8):2423–32. doi:10.1182/blood-2010-08-301945.
Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 2012;122(3):1066–75. doi:10.1172/JCI61226.
Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014;123(5):678–86. doi:10.1182/blood-2013-08-519199.
Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327(17):1209–15 Epub 1992/10/22.
Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 2013;123(6):2447–63. doi:10.1172/JCI64859.
Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010;28(28):4324–32. doi:10.1200/JCO.2010.28.9793.